A phase II clinical trial of Enasidenib in patients with relapsed/refractory IDH2-mutated AML showed that 19.6% of patients achieved complete remission, with a median overall survival of 8.8 months [15]. This evidence concerns the gene IDH2 and acute myeloid leukemia.